Shares of non-opioid painkiller maker Latigo rose modestly after its upsized IPO, signaling investor interest in the biotech's pain management solutions.
BlossomHill's $150 million IPO, backed by Janus Henderson, underscored biotech demand and could lift Janus Henderson's stock on the back of a…
Latigo's $345.6 million IPO highlights Wall Street's bet on non-opioid pain therapies, marking a significant entry for the biotech firm into public…
Braveheart Bio (BRAV) stock price soars 68% on IPO day after a $382.5 million offering backed by A16z, signaling strong demand for…
Braveheart Biotech's $382.5 million upsized IPO underscores robust demand for biotech offerings and may boost sector ETFs like IBB.
AbbVie launches a $10 billion bond offering to finance the Apogee Therapeutics deal, marking a major pharmaceutical M&A debt issuance in 2026.
Latigo files for $288M US IPO to advance its non-opioid painkiller pipeline, capitalizing on strong investor interest in safer alternatives to addictive…
Sleep-apnea biotech Apnimed's stock jumped 38% in its NYSE debut following an upsized US IPO that exceeded initial targets, underscoring strong investor…
Goldman Sachs-backed biotech firm Attovia is seeking $212.5 million in a US IPO, signaling ongoing appetite for healthcare listings amid cautious equity…
Shionogi-backed biotech Apnimed seeks to raise $160 million in a US IPO, highlighting investor appetite for sleep disorder treatments and cross-border healthcare…
Eli Lilly-backed biotech Scribe Therapeutics jumps 50% after upsized IPO, signaling renewed biotech IPO momentum.
Scribe Therapeutics, backed by Eli Lilly, raised $128.7 million in an upsized IPO, reflecting strong investor demand for biotech firms with major…